1. Cancer Network, FDA. Approves Ibrutinib for Chronic Lymphocytic Leukemia, http://www.cancernetwork.com/news/fda-approves-ibrutinib-chronic-lymphocytic-leukemia (accessed 13.11.2014).
2. European Medicines Agency, Imbruvica, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/smops/Positive/human_smop_000721jsp (accessed 13.11.2014).
3. European Medicines Agency, Imbruvica, http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/smops/Positive/human_smop_000822jsp (accessed 22.07.2015).
4. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase;Pan;Chem. Med. Chem.,2007
5. Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis;Whang;Drug Discov. Today,2014